S&P Futures
5,887.75 -8.50 (-0.14%) Dow Futures
43,133.00 -44.00 (-0.10%) Nasdaq Futures
20,473.25 -46.25 (-0.23%) Russell 2000 Futures
2,250.50 -5.00 (-0.22%) Crude Oil
70.27 -0.29 (-0.41%) Gold
2,743.20 +4.30 (+0.16%)
Hoth Therapeutics, Inc. (HOTH)
After hours:
| Previous Close | 0.9285 |
| Open | 0.9332 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.8502 - 0.9332 |
| 52 Week Range | 0.5800 - 1.7300 |
| Volume | |
| Avg. Volume | 3,933,568 |
| Market Cap | 6.075M |
| Beta (5Y Monthly) | 0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5500 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
PR NewswireHoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials.
- PR Newswire
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. In a recent study using Alzheimer's model mice treated with varying doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive functi
